Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Ladan Golestane

Articles by Ladan Golestane

Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System Inhibitors

ByMurray Epstein, MD,Paula J. Alvarez, RPh, MPH, MBA,Nancy L. Reaven, MA,Susan E. Funk, MBA, FACHE,Karen J. McGaughey, PhD,Melanie S. Brenner, PharmD, BCPS,Wade Benton, PharmD,Ladan Golestane

August 31st 2016

Latest Updated Articles

Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System Inhibitors
August 31st 2016

Trending on AJMC

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19

Shields Health Solutions Partners With Baptist Health on Specialty Pharmacy

Special Report: The Oncology Care Model, 10 Years Later

AI Model Challenges Genomic Classifiers in Early Breast Cancer Risk Stratification: Nancy Lin, MD